StockData
Immunome Inc. logo

Immunome Inc. (IMNM) stock

IMNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$17.18−0.43 (-2.44%)

Close on Nov 17, 2026Market cap $1.95BP/E –Yield –

Immunome price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Immunome's price to sales ratio was 373.9× on Apr 30, 2026, against 62.7× a year earlier. Over the last 2 years it ranged from 43.4× to 373.9×, with a median of 74.7×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Apr 30, 2026373.9×+170.4
2025Dec 31, 2025203.5×+140.2
2024Dec 31, 202463.4×–

More Immunome figures

See a number that looks wrong?